Wall Street analysts forecast that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will report sales of $400,000.00 for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Syros Pharmaceuticals’ earnings. The lowest sales estimate is $400,000.00 and the highest is $410,000.00. The firm is expected to report its next earnings results before the market opens on Thursday, March 7th.
On average, analysts expect that Syros Pharmaceuticals will report full-year sales of $1.57 million for the current fiscal year, with estimates ranging from $1.56 million to $1.60 million. For the next financial year, analysts forecast that the firm will post sales of $1.76 million, with estimates ranging from $1.60 million to $2.30 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Syros Pharmaceuticals.
Get Syros Pharmaceuticals alerts:SYRS has been the topic of a number of recent research reports. Roth Capital set a $14.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, December 2nd. Oppenheimer set a $26.00 price objective on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 13th. ValuEngine cut shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. BidaskClub upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, December 11th. Finally, Wedbush reiterated an “outperform” rating and set a $13.00 price objective on shares of Syros Pharmaceuticals in a research report on Monday, December 3rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $17.43.
NASDAQ:SYRS traded down $0.17 during trading hours on Monday, hitting $6.90. 115,909 shares of the stock traded hands, compared to its average volume of 124,286. Syros Pharmaceuticals has a 1 year low of $5.17 and a 1 year high of $13.86. The company has a market capitalization of $230.50 million, a P/E ratio of -3.24 and a beta of 1.14.
Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its position in shares of Syros Pharmaceuticals by 205.9% during the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock valued at $98,000 after buying an additional 11,711 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Syros Pharmaceuticals by 51.4% during the fourth quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock valued at $181,000 after buying an additional 10,995 shares during the last quarter. MetLife Investment Advisors LLC lifted its position in shares of Syros Pharmaceuticals by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock valued at $242,000 after buying an additional 7,230 shares during the last quarter. Alps Advisors Inc. lifted its position in shares of Syros Pharmaceuticals by 30.6% during the fourth quarter. Alps Advisors Inc. now owns 77,768 shares of the company’s stock valued at $433,000 after buying an additional 18,215 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Syros Pharmaceuticals by 8.9% during the fourth quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock valued at $470,000 after buying an additional 6,883 shares during the last quarter. 63.47% of the stock is owned by institutional investors.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Featured Article: QQQ ETF
Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment